GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Down 90.0% in January

GeoVax Labs Inc. (NASDAQ:GOVX) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 151,504 shares, a drop of 90.0% from the December 31st total of 1,514,630 shares. Based on an average daily trading volume, of 211,349 shares, the short-interest ratio is presently 0.7 days. Approximately 12.7% of the company’s stock are sold short. Approximately 12.7% of the company’s stock are sold short. Based on an average daily trading volume, of 211,349 shares, the short-interest ratio is presently 0.7 days.

Analysts Set New Price Targets

GOVX has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. D. Boral Capital reiterated a “buy” rating on shares of GeoVax Labs in a research report on Wednesday, January 21st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $187.50.

Hedge Funds Weigh In On GeoVax Labs

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sabby Management LLC purchased a new position in GeoVax Labs during the third quarter valued at $313,000. Armistice Capital LLC purchased a new stake in GeoVax Labs in the third quarter valued at $253,000. Hudson Bay Capital Management LP acquired a new stake in shares of GeoVax Labs in the third quarter valued at about $47,000. Finally, Jane Street Group LLC purchased a new position in shares of GeoVax Labs in the first quarter worth about $27,000. 6.09% of the stock is owned by institutional investors.

GeoVax Labs Stock Performance

GOVX remained flat at $2.84 on Wednesday. 100,013 shares of the company were exchanged, compared to its average volume of 222,416. GeoVax Labs has a twelve month low of $2.61 and a twelve month high of $51.75. The firm’s fifty day simple moving average is $6.27 and its two-hundred day simple moving average is $12.82. The firm has a market cap of $3.41 million, a PE ratio of -0.08 and a beta of 3.67.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Thursday, November 13th. The company reported ($7.75) EPS for the quarter, missing the consensus estimate of ($6.00) by ($1.75). GeoVax Labs had a negative return on equity of 489.67% and a negative net margin of 403.88%. Research analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.